This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a one week run-in, then will use Tandem Freedom in a supervised hotel setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With One or More Severe Hypoglycemia Events
Timeframe: Control-IQ Run-in Period (7 days), Tandem Freedom (3 days)
Number of Participants With One or More Diabetic Ketoacidosis Events
Timeframe: Control-IQ Run-in Period (7 days), Tandem Freedom (3 days)